<DOC>
	<DOCNO>NCT01041404</DOCNO>
	<brief_summary>This parallel , randomize , open-label , multi-centre study evaluate effect overall survival trastuzumab ( Herceptin ) combination chemotherapy compare chemotherapy alone patient HER2-positive advanced gastric cancer . Trastuzumab ( Herceptin ) administer intravenous infusion 6 mg/kg ( load dose 8 mg/kg ) every 3 week . The chemotherapy consist combination 6 cycle fluorouracil ( 800 mg/m2/day intravenous infusion every 3 week ) cisplatin ( 80 mg/m2 intravenous infusion every 3 week ) , capecitabine ( Xeloda , 1000 mg/m2 po twice daily 14 day every 3 week ) cisplatin ( 80 mg/m2 intravenous infusion every 3 week ) . Treatment trastuzumab ( Herceptin ) continue disease progression . The target sample size 300-600 patient .</brief_summary>
	<brief_title>ToGA Study - A Study Herceptin ( Trastuzumab ) Combination With Chemotherapy Compared With Chemotherapy Alone Patients With HER2-Positive Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adult patient &gt; =18 year age Inoperable locally advance , recurrent , and/or metastatic cancer stomach gastroesophageal junction Adenocarcinoma HER2positive tumor Previous chemotherapy advanced/metastatic disease Lack physical integrity upper gastrointestinal tract , malabsorption syndrome History cardiac disease Dyspnoea rest , due complication advance malignancy disease , patient require supportive oxygen therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>